Search Results - "Maurel, J."

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial by Fernandez-Martos, C., Garcia-Albeniz, X., Pericay, C., Maurel, J., Aparicio, J., Montagut, C., Safont, M.J., Salud, A., Vera, R., Massuti, B., Escudero, P., Alonso, V., Bosch, C., Martin, M., Minsky, B.D.

“…The primary results of our phase II randomized trial suggested that compared with conventional preoperative chemoradiation (CRT), the addition of chemotherapy…”
Get full text

A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer by Leporrier, J., Maurel, J., Chiche, L., Bara, S., Segol, P., Launoy, G.

“…Background: The aim of this population‐based study was to evaluate the incidence, management and prognosis of patients with hepatic metastases related to…”
Get full text

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study by Tempero, M., Oh, D.-Y., Tabernero, J., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D.-T., Starling, N., Bachet, J.-B., Chang, H.-M., Maurel, J., Garcia-Carbonero, R., Lonardi, S., Coussens, L.M., Fong, L., Tsao, L.C., Cole, G., James, D., Macarulla, T.

“…First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase…”
Get full text

Chikungunya outbreak in Montpellier, France, September to October 2014 by Delisle, E, Rousseau, C, Broche, B, Leparc-Goffart, I, L'Ambert, G, Cochet, A, Prat, C, Foulongne, V, Ferre, J B, Catelinois, O, Flusin, O, Tchernonog, E, Moussion, I E, Wiegandt, A, Septfons, A, Mendy, A, Moyano, M B, Laporte, L, Maurel, J, Jourdain, F, Reynes, J, Paty, M C, Golliot, F

“…In October 2014, an outbreak of 12 autochthonous chikungunya cases, 11 confirmed and 1 probable, was detected in a district of Montpellier, a town in the south…”
Get full text

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial by Patel, U.B., Brown, G., Machado, I., Santos-Cores, J., Pericay, C., Ballesteros, E., Salud, A., Isabel-Gil, M., Montagut, C., Maurel, J., Ramón-Ayuso, J., Martin, N., Estevan, R., Fernandez-Martos, C.

“…Primary chemotherapy has been tested as a possible approach for patients with high risk features but predicted clear mesorectal margins on preoperative MRI…”
Get full text

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020) by Gómez-España, Mª A., Montes, A. F., Garcia-Carbonero, R., Mercadé, T. M., Maurel, J., Martín, A. M., Pazo-Cid, R., Vera, R., Carrato, A., Feliu, J.

“…Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the…”
Get full text

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types by Paré, L., Pascual, T., Seguí, E., Teixidó, C., Gonzalez-Cao, M., Galván, P., Rodríguez, A., González, B., Cuatrecasas, M., Pineda, E., Torné, A., Crespo, G., Martin-Algarra, S., Pérez-Ruiz, E., Reig, Ò, Viladot, M., Font, C., Adamo, B., Vidal, M., Gaba, L., Muñoz, M., Victoria, I., Ruiz, G., Viñolas, N., Mellado, B., Maurel, J., Garcia-Corbacho, J., Molina-Vila, M Á, Juan, M., Llovet, J.M., Reguart, N., Arance, A., Prat, A.

“…We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed following anti-PD1…”
Get full text

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer by Ychou, M., Hohenberger, W., Thezenas, S., Navarro, M., Maurel, J., Bokemeyer, C., Shacham-Shmueli, E., Rivera, F., Kwok-Keung Choi, C., Santoro, A.

“…Studies indicate that adjuvant 5-fluorouracil (5-FU) with folinic acid (FA) in colorectal cancer patients with completely resectable liver-limited metastases…”
Get full text

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018) by Gómez-España, M. A., Gallego, J., González-Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliu, J., Vera, R.

“…Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this guide published by the Spanish Society of Medical Oncology is to…”
Get full text

Biliary tract cancers: SEOM clinical guidelines by Benavides, M., Antón, A., Gallego, J., Gómez, M. A., Jiménez-Gordo, A., La Casta, A., Laquente, B., Macarulla, T., Rodríguez-Mowbray, J. R., Maurel, J.

“…Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC),…”
Get full text

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study by Martin-Richard, M., Gallego, R., Pericay, C., Foncillas, J. Garcia, Queralt, B., Casado, E., Barriuso, J., Iranzo, V., Juez, I., Visa, L., Saigi, E., Barnadas, A., Garcia-Albeniz, X., Maurel, J.

“…Summary Background Cisplatin and fluoropyrimidine (CF) are standard first- line treatment in advanced gastric cancer, but no second-line treatment has yet been…”
Get full text

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer by Cohn, A.L., Tabernero, J., Maurel, J., Nowara, E., Sastre, J., Chuah, B.Y.S., Kopp, M.V., Sakaeva, D.D., Mitchell, E.P., Dubey, S., Suzuki, S., Hei, Y.-J., Galimi, F., McCaffery, I., Pan, Y., Loberg, R., Cottrell, S., Choo, S.-P.

“…Targeted agents presently available for mutant KRAS metastatic colorectal cancer (mCRC) are bevacizumab and aflibercept. We evaluated the efficacy and safety…”
Get full text

Lithium as a disease-modifying agent for prion diseases by Relaño-Ginés, A., Lehmann, S., Brillaud, E., Belondrade, M., Casanova, D., Hamela, C., Vincent, C., Poupeau, S., Sarniguet, J., Alvarez, T., Arnaud, J. D., Maurel, J. C., Crozet, C.

“…Prion diseases still remain incurable despite multiple efforts to develop a treatment. Therefore, it is important to find strategies to at least reduce the…”
Get full text

Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study by Custodio, A., Moreno-Rubio, J., Aparicio, J., Gallego-Plazas, J., Yaya, R., Maurel, J., Higuera, O., Burgos, E., Ramos, D., Calatrava, A., Andrada, E., López, R., Moreno, V., Madero, R., Cejas, P., Feliu, J.

“…Oxaliplatin-based chemotherapy (CT), widely used as adjuvant therapy for stage III and selected high-risk stage II colon cancer (CC) patients, is often…”
Get full text

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS) by Mora, J, Castañeda, A, Perez-Jaume, S, Lopez-Pousa, A, Maradiegue, E, Valverde, C, Martin-Broto, J, Garcia del Muro, X, Cruz, O, Cruz, J, Martinez-Trufero, J, Maurel, J, Vaz, M A, de Alava, E, de Torres, C

“…Background: First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in…”
Get full text

Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)? by Reyes, R., Ayuso, J., Pagés, M., Conill, C., Darnell, A., Pineda, E., Gines, A., Fernández-Esparrach, M., Cuatrecasas, M., Moreno, R., Lacy, A., Pellisé, M., Maurel, J.

Get full text

Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis by Trilla, L., Ghanem, I., Gámez, A., Maurel, J., Campos-Barros, À, G-Pastrián, L., Mendiola, M., Peña, C., Cuatrecasas, M., García Alfonso, P., Fresno, J., Feliu, J.

Get full text

Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis by Ghanem, I., Trilla, L., Gámez, A., Mendiola, M., Maurel, J., Campos-Barros, à., Peña, C., Cuatrecasas, M., G-Pastrián, L., García Alfonso, P., Feliu, J., Fresno, J.

Get full text

Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study by Tempero, M., Oh, D., Macarulla, T., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D., Starling, N., Bachet, J., Chang, H., Maurel, J., Lonardi, S., Coussens, L., Fong, L., Tsao, L., Cole, G., James, D., Tabernero, J.

Get full text

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy by Van Cutsem, E., Siena, S., Humblet, Y., Canon, J.-L., Maurel, J., Bajetta, E., Neyns, B., Kotasek, D., Santoro, A., Scheithauer, W., Spadafora, S., Amado, R. G., Hogan, N., Peeters, M.

“…Background: A phase 3 study demonstrated that panitumumab, a human monoclonal anti-epidermal growth factor receptor antibody, significantly prolonged…”
Get full text